Dendritic cell vaccination in glioblastoma after fluorescence-guided resection

doi:10.5306/wjco.v3.i11.142

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 11

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5446)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

445

HTML

3207

Figures (1-2)

173

Tables (1-3)

182

Sum=4007

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1094

Download

342

Sum=1436

Nov 10, 2012 (publication date) through Aug 31, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Original Article

World J Clin Oncol. Nov 10, 2012; 3(11): 142-149
Published online Nov 10, 2012. doi: 10.5306/wjco.v3.i11.142

Table 1 Patients characteristics

Patient	Age(yr)	KPS(%)	RPA	Sex	MMSE score	Tumor volume (cc)	MGMT promoter	Tumor location	PFS (mo)	OS (mo)
1	69	70	5	M	28	111.8	Methylated	right frontal	19.5	27.0
2	73	70	5	M	27	34.0	Unmethylated	left temporal	3.1	9.1
3	50	80	5	F	26	12.9	Methylated	left temporal	3.2	> 36.0
4	67	60	5	F	28	68.3	Methylated	right frontal	16.1	27.4
5	71	90	4	F	30	44.8	Methylated	right frontal	20.3	> 32.0

KPS: Karnofsky performance status; MMSE: Mini mental state examination; MGMT: Status of O⁶-methylguanine-DNA methyltransferase; PFS: Progression free survival; OS: Overall survival; RPA: Recursive partitioning analysis.

Table 2 Summary of vaccine production data

	Number of producedvaccine doses	Number of administratedvaccine doses	Number of DC/dose		Amount tumor lysate (mg/mL)/10⁷ iDC
			Range	Mean
UPN 1	16	11	10.00-10.00 × 10⁶	10.00 × 10⁶	67.4 (33.7 CP + 33.7 IP)
UPN 2	18	4	8.25-9.20 × 10⁶	8.85 × 10⁶	52.75 (CP)
UPN 3	4	4	2.30-6.80 × 10⁶	3.40 × 10⁶	75 (CP)
UPN 4	15	15	0.82-10.00 × 10⁶	4.90 × 10⁶	75 (37.5 CP + 37.5 IP) / 50 (20 CP + 30 IP)
UPN 5	16	12	1.00-10.00 × 10⁶	4.89 × 10⁶	75 (19 CP + 56 IP)

UPN: Unique patient number; DC: Dendritic cells; iDC: Immature dendritic cells; CP: Central portion; IP: Invasive portion.

Table 3 Summary of immune responses

Patient	Cellular response
	Proliferation			Cytokines
	DC	Tumor lysate		IFN-γ						TNF-α
		Centralportion	Invasiveportion	ELISA			ELISPOT			ELISA
				DC	Tumor lysate		DC	Tumor lysate		DC	Tumor lysate
				DC	Central portion	Invasive portion		Central portion	Invasive portion	DC	Central portion	Invasive portion
UPN 1	+	-	ND	+	-	ND	DC	-	-	ND	-	-	ND
UPN 2	+	-	ND	+	-	ND	-	-	ND	-	-	ND
UPN 3	ND	-	ND	ND	-	ND	ND	-	ND	ND	-	ND
UPN 4	ND	-	-	ND	-	-	ND	-	-	ND	-	-
UPN 5	+	-	-	+	+	+	-	-	-	-	-	-

DC: Dendritic cells; ND: Not determined due to insufficient material. IFN: Interferon; TNF-α: Tumor necrosis factor α.

Citation: Valle RD, Cerio ALD, Inoges S, Tejada S, Pastor F, Villanueva H, Gallego J, Espinos J, Aristu J, Idoate MA, Andreu E, Bendandi M. Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol 2012; 3(11): 142-149
URL: https://www.wjgnet.com/2218-4333/full/v3/i11/142.htm
DOI: https://dx.doi.org/10.5306/wjco.v3.i11.142